Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule

Enrollment continues in EMBRACE, the second pivotal study of the Phase 3 PARADIGM Program Participant rollover is ongoing into the EXTEND long-term study generating long-term safety and durability data APPROACH topline data readout on track for Q4 20261,2 HLP003 previously granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (“FDA”) HLP003 Phase 2 […]

Enrollment continues in EMBRACE, the second pivotal study of the Phase 3 PARADIGM Program Participant rollover is ongoing into the EXTEND long-term study generating long-term safety and durability data APPROACH topline data readout on track for Q4 20261,2 HLP003 previously granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (“FDA”) HLP003 Phase 2 […]